Skip to main content

Clinical trial CHRONOS-4

A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)

Organ Lymphome non-hodgkinien
Trial status Trial closed for recruitment
Trial type
Interventionnal with IMP
Phase Trial phase 3
Academic trial Non
Sponsor Bayer
EudraCT Identifier 2015-001088-38
Inclusion criteria 2nd to 4th line / at least 1 bi-dimensionaly measurable lesion/ HbA1c
Last update